Azacitidine

Azacitidine is a cytadine analogue that can be incorporated into RNA and DNA. Azacitidine is investigational antineoplastic drug. Azacitidine is antineoplastic agent. It belongs to antimetabolites. Antimetabolites are the compounds that bear a structural similarity to a naturally occuring substance, such as vitamin, nucleoside or amino acid. Azacitidine is effective in the treatment of different cancers to slow or stop the growth of abnormal cells. Azacitidine is used in combination with different anticancerous drugs to obtain most excellent therapeutic effects and minimize unwanted effects or toxicities. it has been used mainly in the treatment of acute non-lymphoblastic leukemia.

Brands
Adult Dose
Dose: 1.25 to 1.666 mg/sq.meter
Single Dose: 1.5 (1.458)
Frequency: As recommended.
Route: IV Inf
Instructions: Upto 2 hours for 5 days a week per 2 weeks
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to Ribofuranosyltriazin. It belongs to RNA polymerase substrate pharmacological group on the basis of mechanism of action and also classified in Chemotherapeutic Regimens and Antineoplastic Agent pharmacological group.The Molecular Weight of Azacitidine is 244.20.
Contraindications
Azacitidine is contraindicated in conditions like Non malignant conditions.
Effects
The severe or irreversible adverse effects of Azacitidine, which give rise to further complications include Myeloid leukemia, Carcinogenic risk.Azacitidine produces potentially life-threatening effects which include Severe Hypotension. which are responsible for the discontinuation of Azacitidine therapy.The signs and symptoms that are produced after the acute overdosage of Azacitidine include Hypotension, Nausea, Vomiting, Diarrhea, Myelosuppression.The symptomatic adverse reactions produced by Azacitidine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Diarrhea.
Indications
Azacitidine is primarily indicated in conditions like Acute myeloid leukemia, Beta thalassaemia, Sickle cell anaemia.
Interactions
No data regarding the interactions of Azacitidine was found.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
solutions,injections,powder Store in a well closed container, Between 15°C-30°C. Protect from Sunlight, Moisture and Heat.
Warnings
Azacitidine is not recommended for use during pregnancy or lactation. Immunosuppressant drug should not be given, where possible, to patients with acute infection, dosage reduction or withdrawal should be considered if infection develops, until the infection has been controlled. Blood counts and measurment of haemoglobin concentration should be carried out routinely, it help to predict the onset of bone marrow depression. It must be handled with great care and avoid contact with skin and eyes and should not be inhaled.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.